The use of PCSK9 inhibitor alirocumab for LDL-cholesterol lowering in post-ACS patients does not appear to have any adverse glucometabolic effect on people regardless of glycaemic status. Speaking at the 2018 ADA Scientific Sessions in Orlando, cardiologist Professor Kausik Ray said the pre-specified analyses of the ODYSSEY Outcomes study showed no signal for new onset ...
Ischaemic heart disease
PCSK9 inhibitor no risk for diabetes
By Mardi Chapman
6 Jul 2018